Skip to main content

Table 3 Statistical comparisons of PK parameters of metformin, remogliflozin etabonate, remogliflozin, and GSK279782 with and without remogliflozin etabonate

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Compound PK parameter Treatment comparison Point estimate (GLSM Ratio) 90% CI
Metformin AUC(0–12) [1] MET + RE / MET 1.05 (0.98, 1.12)
  Cmax MET + RE / MET 1.01 (0.92, 1.10)
Remogliflozin etabonate (prodrug) AUC(0-last) MET + RE / RE 1.00 (0.77, 1.29)
  Cmax MET + RE / RE 0.85 (0.54, 1.35)
Remogliflozin (active entity) AUC(0–12) MET + RE / RE 0.94 (0.86, 1.04)
  Cmax MET + RE / RE 0.79 (0.60, 1.05)
GSK279782 (active metabolite) AUC(0–12) MET + RE / RE 0.96 (0.92, 1.01)
  Cmax MET + RE / RE 0.78 (0.67, 0.91)
  1. [1] primary comparison; MET + RE, metformin 500 mg + remogliflozin etabonate 500 mg every 12 hours; GLSM : Geometric least-squares mean.